Advertisement
Canada markets close in 3 hours 39 minutes
  • S&P/TSX

    22,181.91
    +74.83 (+0.34%)
     
  • S&P 500

    5,252.28
    +3.79 (+0.07%)
     
  • DOW

    39,785.35
    +25.27 (+0.06%)
     
  • CAD/USD

    0.7385
    +0.0013 (+0.18%)
     
  • CRUDE OIL

    82.54
    +1.19 (+1.46%)
     
  • Bitcoin CAD

    95,712.62
    +2,559.35 (+2.75%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,234.40
    +21.70 (+0.98%)
     
  • RUSSELL 2000

    2,134.14
    +19.79 (+0.94%)
     
  • 10-Yr Bond

    4.1870
    -0.0090 (-0.21%)
     
  • NASDAQ

    16,387.67
    -11.85 (-0.07%)
     
  • VOLATILITY

    12.85
    +0.07 (+0.55%)
     
  • FTSE

    7,966.00
    +34.02 (+0.43%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • CAD/EUR

    0.6837
    +0.0032 (+0.47%)
     

Hutchison China MediTech (HCM) Is Up 0.6% in One Week: What You Should Know

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.

While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.

Below, we take a look at Hutchison China MediTech (HCM), a company that currently holds a Momentum Style Score of A. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Hutchison China MediTech currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.

ADVERTISEMENT

You can see the current list of Zacks #1 Rank Stocks here >>>

Set to Beat the Market?

In order to see if HCM is a promising momentum pick, let's examine some Momentum Style elements to see if this provider of drug research and development services holds up.

Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It's also helpful to compare a security to its industry; this can show investors the best companies in a particular area.

For HCM, shares are up 0.6% over the past week while the Zacks Medical - Products industry is flat over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 17.19% compares favorably with the industry's 3.84% performance as well.

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Hutchison China MediTech have increased 35.42% over the past quarter, and have gained 28.65% in the last year. On the other hand, the S&P 500 has only moved 10.34% and 28.32%, respectively.

Investors should also take note of HCM's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now, HCM is averaging 147,517 shares for the last 20 days.

Earnings Outlook

The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with HCM.

Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. These revisions helped boost HCM's consensus estimate, increasing from -$1.39 to -$1.25 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.

Bottom Line

Taking into account all of these elements, it should come as no surprise that HCM is a #2 (Buy) stock with a Momentum Score of A. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Hutchison China MediTech on your short list.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Hutchison China MediTech Limited (HCM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.